TR200101893T2 - Antiviral maddeler olarak 4-okso-1,4 dihidro -3- kuinolinkarboksamitler. - Google Patents

Antiviral maddeler olarak 4-okso-1,4 dihidro -3- kuinolinkarboksamitler.

Info

Publication number
TR200101893T2
TR200101893T2 TR2001/01893T TR200101893T TR200101893T2 TR 200101893 T2 TR200101893 T2 TR 200101893T2 TR 2001/01893 T TR2001/01893 T TR 2001/01893T TR 200101893 T TR200101893 T TR 200101893T TR 200101893 T2 TR200101893 T2 TR 200101893T2
Authority
TR
Turkey
Prior art keywords
quinolinecarboxamides
dihydro
oxo
formula
antiviral agents
Prior art date
Application number
TR2001/01893T
Other languages
English (en)
Inventor
Ronald Turner Steven
Walter Strohbach Joseph
Thaisrivongs Suvit
A. Vaillancourt Valerie
E. Schnute Mark
Scott Allen
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of TR200101893T2 publication Critical patent/TR200101893T2/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formül I bir bilesik, (FORMÜL) burada, R1 istege bagli olarak hidroksi veya NR4R5 ile ikameli C1-7 alkildir; R2 hidroksi veya NR4R5 ile ikameli C1-7 alkildir; R3H, F veya C1-7 alkoksidir; R4 ve R5 N ile birlikte azot, oksijen ve kükürtten olusan gruptan seçilmis 1-3 heteroatoma sahip 5 veya 6 unsurlu heteroksiklik bir yarimdir, burada kükürt bir (1) veya iki (2) oksijen atomu ile ikame edilebilir; ve bunun farmasötik açidan kabul edilebilir bir tuzdur. Mevcut bulusa mahsus formül I bilesikler intiviral maddeler olarak faydalidirlar.
TR2001/01893T 1999-01-08 1999-12-22 Antiviral maddeler olarak 4-okso-1,4 dihidro -3- kuinolinkarboksamitler. TR200101893T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11511399P 1999-01-08 1999-01-08
US13839099P 1999-06-09 1999-06-09
US14061499P 1999-06-23 1999-06-23

Publications (1)

Publication Number Publication Date
TR200101893T2 true TR200101893T2 (tr) 2001-11-21

Family

ID=27381602

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01893T TR200101893T2 (tr) 1999-01-08 1999-12-22 Antiviral maddeler olarak 4-okso-1,4 dihidro -3- kuinolinkarboksamitler.

Country Status (27)

Country Link
US (1) US6248736B1 (tr)
EP (1) EP1140851B1 (tr)
JP (1) JP2002534417A (tr)
KR (1) KR20010101428A (tr)
CN (1) CN1132818C (tr)
AT (1) ATE275134T1 (tr)
AU (1) AU2158300A (tr)
BR (1) BR9916781A (tr)
CA (1) CA2353634A1 (tr)
CO (1) CO5150150A1 (tr)
CZ (1) CZ20012458A3 (tr)
DE (1) DE69919897T2 (tr)
EA (1) EA004043B1 (tr)
ES (1) ES2228162T3 (tr)
HU (1) HUP0105142A3 (tr)
ID (1) ID29452A (tr)
IL (1) IL144170A0 (tr)
MY (1) MY118904A (tr)
NO (1) NO320396B1 (tr)
NZ (1) NZ512823A (tr)
PE (1) PE20001337A1 (tr)
PL (1) PL348769A1 (tr)
PT (1) PT1140851E (tr)
SK (1) SK8312001A3 (tr)
TR (1) TR200101893T2 (tr)
TW (1) TW593281B (tr)
WO (1) WO2000040563A1 (tr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6682892B2 (en) * 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
CA2433467A1 (en) * 2001-03-01 2002-09-12 Joseph W. Strohbach Substituted quinolinecarboxamides as antiviral agents
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
AR038117A1 (es) 2002-01-14 2004-12-29 Upjohn Co Agentes antivirales derivados de la 4- oxo-4,7 -dihidrofuro [2,3-b]piridin-5-carboxamida
AR038294A1 (es) 2002-01-14 2005-01-12 Upjohn Co Oxotieno(3,2-b)piridincarboxamidas como agentes antivirales
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US20040186131A1 (en) * 2002-08-30 2004-09-23 Wathen Michael W Method of preventing or treating atherosclerosis or restenosis
AU2003262946A1 (en) * 2002-08-30 2004-03-19 Pharmacia And Upjohn Company Method of preventing or treating atherosclerosis or restenosis
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
WO2004046115A1 (ja) * 2002-11-20 2004-06-03 Japan Tobacco Inc. 4−オキソキノリン化合物及びそのhivインテグラーゼ阻害剤としての利用
US7488739B2 (en) 2003-07-24 2009-02-10 Astellas Pharma Inc. Quinolone derivative or salt thereof
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP2229945A1 (en) 2004-05-21 2010-09-22 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
US20070032522A1 (en) * 2005-07-01 2007-02-08 Kumar Dange V Antiviral agents
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
JP2009525261A (ja) * 2006-02-01 2009-07-09 日本たばこ産業株式会社 レトロウイルス感染症の治療のための、6−(3−クロロ−2−フルオロベンジル)−1−[(2s)−1−ヒドロキシ−3−メチルブタン−2−イル]−7−メトキシ−4−オキソ−1,4−ジヒドロキノリン−3−カルボン酸またはその塩の使用
KR101023635B1 (ko) * 2006-03-06 2011-03-22 니뽄 다바코 산교 가부시키가이샤 4-옥소퀴놀린 화합물 제조 방법
DE102008036099B4 (de) 2008-08-04 2014-02-13 Steag Power Saar Gmbh Entstickungsanlage
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
KR101727762B1 (ko) 2009-03-20 2017-04-17 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
WO2011004389A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
KR20130100300A (ko) * 2010-08-27 2013-09-10 그뤼넨탈 게엠베하 Kcnq2/3 조절제로서의 치환된 2-옥시-퀴놀린-3-카복스아미드
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 薬学的組成物およびその投与
US9309222B2 (en) 2012-10-16 2016-04-12 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
CN104884448A (zh) 2012-10-16 2015-09-02 詹森药业有限公司 Rorγt的杂芳基连接的喹啉基调节剂
JP6466335B2 (ja) 2012-10-16 2019-02-06 ヤンセン ファーマシューティカ エヌ.ベー. ROR−γ−Tのメチレン連結キノリニルモジュレーター
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
CN105873439A (zh) 2013-10-15 2016-08-17 詹森药业有限公司 RORγt的烷基连接的喹啉基调节剂
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
AU2019339777B2 (en) 2018-09-12 2022-09-01 Novartis Ag Antiviral pyridopyrazinedione compounds
US11667613B2 (en) 2019-09-26 2023-06-06 Novartis Ag Antiviral pyrazolopyridinone compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593810B1 (fr) * 1986-01-24 1988-04-22 Sanofi Sa Derives de la quinoleine, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
US5175151A (en) 1990-09-07 1992-12-29 Schering Corporation Antiviral compounds and antihypertensive compounds
JPH06502845A (ja) * 1990-09-07 1994-03-31 シェリング・コーポレーション 抗ウイルス化合物および抗高血圧化合物
DE69115692T2 (de) 1991-09-10 1996-08-01 Agfa Gevaert Nv Thermisch übertragbare fluoreszierende Verbindungen
PT841929E (pt) * 1995-08-02 2003-09-30 Darwin Discovery Ltd Quinolonas e sua utilizacao terapeutica
AU7333496A (en) 1995-10-19 1997-05-07 Takeda Chemical Industries Ltd. Quinoline derivatives as gnrh antagonists
WO1998023608A1 (en) 1996-11-27 1998-06-04 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
RU2220960C2 (ru) 1997-12-22 2004-01-10 Фармация Энд Апджон Компани 4-гидрокси-3-хинолинкарбоксамиды и гидразиды, фармацевтическая композиция и способ лечения на их основе

Also Published As

Publication number Publication date
TW593281B (en) 2004-06-21
IL144170A0 (en) 2002-05-23
BR9916781A (pt) 2001-12-04
SK8312001A3 (en) 2001-12-03
ATE275134T1 (de) 2004-09-15
EP1140851B1 (en) 2004-09-01
DE69919897T2 (de) 2005-09-08
JP2002534417A (ja) 2002-10-15
EP1140851A1 (en) 2001-10-10
HUP0105142A2 (hu) 2002-04-29
EA004043B1 (ru) 2003-12-25
AU2158300A (en) 2000-07-24
MY118904A (en) 2005-02-28
PE20001337A1 (es) 2000-11-23
CN1332729A (zh) 2002-01-23
CA2353634A1 (en) 2000-07-13
WO2000040563A1 (en) 2000-07-13
NZ512823A (en) 2003-10-31
KR20010101428A (ko) 2001-11-14
PL348769A1 (en) 2002-06-17
EA200100755A1 (ru) 2001-12-24
ES2228162T3 (es) 2005-04-01
ID29452A (id) 2001-08-30
CN1132818C (zh) 2003-12-31
PT1140851E (pt) 2004-12-31
HK1041879A1 (en) 2002-07-26
NO20013379D0 (no) 2001-07-06
NO20013379L (no) 2001-07-06
CZ20012458A3 (cs) 2001-12-12
US6248736B1 (en) 2001-06-19
DE69919897D1 (en) 2004-10-07
HUP0105142A3 (en) 2002-05-28
CO5150150A1 (es) 2002-04-29
NO320396B1 (no) 2005-11-28

Similar Documents

Publication Publication Date Title
NO20013379D0 (no) 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler
ATE270278T1 (de) Phthalazinone pde iii/iv hemmer
DK1054874T3 (da) Substituerede aminophenylisoxazolinderivater, der er anvendelige som antimokrobielle midler
DE69213216D1 (de) Quarternäre panthenolderivate und ihre verwendung
ES8600288A1 (es) Un procedimiento para la preparacion de derivados de quinolina.
MXPA02004440A (es) Derivados de pirrol como inhibidores de la fosfodiesterasa vii.
PT918776E (pt) Sintese total de acilfulvenos antitumorais
DE69505470D1 (de) Pyrrolocarbazol
DK1042319T3 (da) Dihydrobenzofuraner
TR200100603T2 (tr) Pirazin bileşikleri
PT1044186E (pt) Composto 2-benzilamino-2-fenil-acetamida substituidos
TR200200360T2 (tr) Antibakteriyel aktif maddeler.
SE8503415D0 (sv) Novel isoindolinyl-alkyl-piperazines
ATE259813T1 (de) Triazolopyrimidinderivate
TR200003652T2 (tr) Glisin antagonistleri olarak tetrahidrokuinolin türevleri.
DE60036558D1 (de) Phthalazinon-derivate als pde 4 hemmer
NZ336091A (en) Aqueous disinfecting cleaning composition
DK0623131T3 (da) Alkylderivater af trazodon med CNS-aktivitet
KR960702463A (ko) Dc-89 유도체[dc-89 derivative]
DK0594329T3 (da) Antimikrobielle midler, der omfatter polykvaternære ammoniumforbindelser
NZ333854A (en) Intermediates for the preparation of 2-imidazoline-5-ones
EA200000681A1 (ru) Фунгицидная смесь на базе амидных соединений и производных пиридина
KR920012100A (ko) 비스포스폰산 유도체, 이의 제조 및 용도
TW330147B (en) Halogenobenzimidazoles, their preparation processes and their use
BR8003950A (pt) Composicoes herbicidas, baseadas em derivados de m-anilido-uretana